The HeartPad® and HeartPad®Mini are not for sale in the United States. They are delivered and positioned adjacent to the heart using video guidance and/or 3D-mapping, for minimally invasive ablation procedures. They are intended to ablate generally large contiguous areas of cardiac tissue, such as atrial and ventricular tissue. Once in position the device is expanded by inflating its pressure-controlled insulation pontoon. This brings the unique ablating surface into contact with an external (epicardial) surface of the heart that is targeted for ablation. System sensors provide data to help direct ablation therapy. Extremely low temperature (“XLT”) helium gas is driven through the unique ablating surface, attaching the ablation pad to the heart by a process called cryo-adhesion. The contacted surface of the heart is ablated while adjacent areas are protected from ablation injury by the insulation pontoon. After ablation is completed warm gas is supplied to thaw the ablation pad which reverses the cryo-adhesion and allows re-positioning of the device if additional ablation is required. The HeartPad® is then collapsed and withdrawn from the pericardial cavity.
Introducing the HeartPad®
Left Atrial Ablation
Pulmonary Artery Denervation
Left Atrial Appendage/Vein and Ligament of Marshall Management via SubX Access
Minimally Invasive Cryoablation of Solid Tumors
Ablation is a general methodology to destroy or disable abnormal tissue in the body that is causing disease or dysfunction. Ablation therapies have been used to destroy cancerous tumors and to disrupt electrical energy that causes heart rhythm disturbances. Many energy sources can be used for ablation, including extreme heat, microwave, ultrasound, laser, and cryothermy (freezing).